Actively Recruiting
MISC COVID-19 Study in Pediatric Population
Led by Tuberculosis Research Centre, India · Updated on 2024-05-30
180
Participants Needed
1
Research Sites
209 weeks
Total Duration
On this page
Sponsors
T
Tuberculosis Research Centre, India
Lead Sponsor
N
National Institutes of Health (NIH)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Rationale: Severe Acute Respiratory Syndrome - Coronavirus - 2 (SARS-CoV2) and its related Coronavirus Disease - 19 (COVID-19) has become a health emergency worldwide. The medical community has been concerned since the beginning of the outbreak about the potential impact of COVID-19 in children, especially in those with underlying chronic diseases. Fortunately, COVID-19 has been reported to be less severe in children than in adults. Unfortunately, a new multisystem inflammatory syndrome apparently related to infection with SARS-CoV-2 has recently been reported in older children (known as MIS-C), manifested by severe abdominal pain, cardiac dysfunction and shock. However, the SARS-CoV2 infection and the underlying immunology of COVID-19, its correlation with disease severity and MIS-C in children is not fully explored. Objectives: To perform systems immunology and strain diversity among SARS-CoV2 and MIS-C infected children. Study design: Cross sectional study. Study population: Children attending outpatients units and admitted in wards in pediatric hospitals in Chennai. Main study parameters/endpoints: Immune responses in children with SARS-CoV2 infection and multisystem inflammatory syndrome in children (MIS-C) infection and its association of SARS-CoV2 viral diversity.
CONDITIONS
Official Title
MISC COVID-19 Study in Pediatric Population
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Children between 1 to 15 years of age
- Willing to provide informed consent (parents)/assent
- For Group 1: Positive or Negative for COVID-19 by RT-PCR but positive for SARS-CoV2 IgG
- For Group 2: Positive for COVID-19 by RT-PCR but negative for SARS-CoV2 IgG
- For Group 3: Positive for COVID-19 by RT-PCR or positive for SARS-CoV2 IgG antibody
- For Group 4: Control children who are negative for both RT-PCR and IgG antibody
You will not qualify if you...
- Severely immunocompromised or anemic (WHO criteria in children) or malnourished
- History of any illness or condition which, in the investigator's judgment, may substantially increase the risk associated with the participant's participation in the protocol, or compromise the scientific objectives
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Institute for Research in Tuberculosis
Chennai, Tamil Nadu, India, 600031
Actively Recruiting
Research Team
P
PAVAN KUMAR, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here